Artigo
Revisado por pares
Abstract CT183: Final five year median follow-up data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating a time series of immune responses using HER2/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer
2021; SAGE Publishing; Linguagem: Inglês
10.1158/1538-7445.am2021-ct183
ISSN1740-7753
AutoresSnehal S. Patel, David B. McWilliams, Mira S. Patel, Christine T. Fischette, Jaye Thompson, F Joseph Daugherty,
Tópico(s)Immunotherapy and Immune Responses
Referência(s)